AstraZeneca Plc has reported positive data from a Phase 3 trial of its antibody-drug conjugate datopotamab deruxtecan in patients with metastatic hormone receptor (HR) positive, HER2-low or negative breast cancer, the most common breast cancer subtype, accounting for more than 65% of cases diagnosed globally. The trial enrolled 700 patients across five continents.
